Henry McCance, Founding Board Member Henry McCance is a Founding Board member of Cure Alzheimerās Fund and Chairman of Greylock Partners, a leading venture capital firm with a distinguished and highly successful record of company building. His family situation brought him to this effort as his words describe here. Many people have ...
August 20, 2009
āFor the first time, and to the astonishment of many of their colleagues, researchers created what they call Alzheimerās in a Dish ā a petri dish with human brain cells that develop the telltale structures of Alzheimerās disease.ā So begins a new story in the New York Times by science reporter ...
October 13, 2014
Apolipoprotein E (APOE), the most important genetic predisposition factor for Alzheimerās disease (AD), long has been known for its effect on the formation of amyloid plaques and, more recently, for its importance in glial cell activation. There is evidence for another role of APOE on neuron function independent of amyloid ...
December 22, 2022
The goal of this project is to test whether the strategy of stimulating endogenous stem cells in the AD brain is safe in order to find treatment for Alzheimerās patients. Recent evidence shows the adult brain contains discrete populations of stem cells that retain the capacity to generate new neurons through ...
November 9, 2011
2024 Naturally occurring antibodies (Nabs) in human blood are the front line of defense against a broad range of infectious agents, and antibodies are increasingly useful and important therapeutic agents against human disease. Three antibodies against amyloid beta (Aducanumab, Lecanemab, and Donanemab) are the first disease-modifying drugs for Alzheimerās disease (AD) ...
September 19, 2023
On July 2, the FDA approved donanemab for the treatment of early symptomatic Alzheimerās disease.Ā Donanemab will be sold under the brand name Kisunlaā¢ and will be delivered via once-monthly IV infusion.Ā The annual drug cost of Kisunla alone ā not including provider or administration costs ā is set at $32,000, ...
July 3, 2024
The loss of synapses in the brain is a characteristic hallmark of Alzheimerās disease (AD) and is responsible for memory impairment. The assessment of synaptic degeneration is therefore important to detect positive effects in drug development and for early diagnosis. We recently showed that the measurement of the protein beta-synuclein ...
September 19, 2023
It may not be surprising to learn that brain health is intricately linked to the state of the rest of the body. But what are the links, and what role do these connections play in diseases like Alzheimerās? Sam Sisodia, Ph.D., of the University of Chicago, is examining one of ...
March 14, 2017
High blood pressure or arterial hypertension, a condition affecting 30% of the US population, has damaging effects on the brain, including increasing the risk for Alzheimerās disease. How hypertension promotes the development of Alzheimerās disease is not clear, but it has been attributed to damage to the blood vessels of ...
June 28, 2024
There is a growing recognition that the immune system plays a key role in damaging brain cells during the progression of Alzheimerās disease. While the immune system is normally protective against foreign invaders such as viruses or bacteria, it can become dysregulated in diseases such as Alzheimerās disease, attack neurons, ...
June 26, 2024
